Formycon AG (ETR: FYB)
Germany
· Delayed Price · Currency is EUR
55.00
-1.40 (-2.48%)
Jan 21, 2025, 10:59 AM CET
Formycon AG Employees
Formycon AG had 238 employees as of December 31, 2023. The number of employees increased by 33 or 16.10% compared to the previous year.
Employees
238
Change (1Y)
33
Growth (1Y)
16.10%
Revenue / Employee
€254,393
Profits / Employee
€267,351
Market Cap
995.85M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Merck KGaA | 62,908 |
Siemens Healthineers AG | 72,000 |
Bayer Aktiengesellschaft | 96,931 |
Fresenius SE & Co. KGaA | 193,865 |
Sartorius Aktiengesellschaft | 14,614 |
Fresenius Medical Care AG | 119,845 |
Carl Zeiss Meditec AG | 5,730 |
SCHOTT Pharma AG & Co. KGaA | 4,690 |
Formycon AG News
- 1 day ago - EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea, under the brand names AHZANTIVE and Baiama - Wallstreet:Online
- 6 days ago - EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi (ustekinumab), a biosimilar to Stelara - Wallstreet:Online
- 8 days ago - EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea/ aflibercept) in major parts of Europe and Israel - Wallstreet:Online
- 8 days ago - Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea (aflibercept) in major parts of Europe and in Israel - Wallstreet:Online
- 11 days ago - EQS-News: Formycon included in TecDAX Index of Deutsche Börse - Wallstreet:Online
- 12 days ago - EQS-News: Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi (ustekinumab), a biosimilar to Stelara - Wallstreet:Online
- 6 weeks ago - EQS-News: MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region - Wallstreet:Online
- 7 weeks ago - Formycon AG (XTER:FYB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Revenue Challenges - GuruFocus